Taxol^® is a relatively new antineoplastic agent whose classification as vesicant, non-vesicant, or irritant remains under debate. This case study is presented to follow a large-volume Taxol^® extravasation. The article illustrates assessment, follow-up, intervention and outcome of this situation. This case suggests the drug is a vesicant with the potential to cause moderate soft tissue injury.

Canadian Oncology Nursing Journal 7/2/97